Clinical laboratory and contract research organization businesses that earn fee-for-service revenue by processing diagnostic tests, specialty / genomic assays, central-lab work, and outsourced clinical-trial services. Revenue is driven by testing volume, reimbursement / price per requisition, specialty mix, trial-service awards, backlog conversion, and working-capital collection efficiency. The te
| Ticker | Company | Their metric | Period | YoY | A year ago |
|---|---|---|---|---|---|
| GH | Guardant Health, Inc. | Clinical tests | FY2026-Q2 | +62.5% | +29.6% |
| MEDP | Medpace Holdings, Inc. | Ending backlog | FY2026-Q2 | +4.9% | -1.8% |
| ADPT | Adaptive Biotechnologies Corporation | ClonoSEQ Test Volume | FY2026-Q2 | +42.6% | +36.7% |
| IQV | IQVIA Holdings Inc. | Contracted backlog | FY2026-Q2 | +6.5% | +4.9% |
| MYGN | Myriad Genetics, Inc. | Total test results delivered | FY2026-Q2 | -1.3% | -1.3% |
| FTRE | Fortrea Holdings Inc. | Fortria Backlog | FY2026-Q1 | +1.6% | +4.0% |
| OABI | OmniAb, Inc. | Active partners | FY2026-Q2 | +10.0% | +20.5% |
| VCYT | Veracyte, Inc. | Decipher test volume | FY2026-Q2 | +16.5% | +28.1% |
| CSTL | Castle Biosciences, Inc. | DecisionDx-SCC Test Reports | FY2026-Q2 | -15.8% | +11.3% |
| NTRA | Natera, Inc. | Loss from operations (GAAP) | FY2025-Q3 | +148.3% | -64.6% |
A side-by-side appears only when three or more companies report the same metric in the same unit under their own definition. Companies are listed in value order, not ranked: whether a higher number is better is not asserted.